Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are overlapping inflammatory rheumatic disorders commonly affecting older people 1 . Although reports by Horton (in 1932) 2 , Paulley and Hughes (in 1960) 3 and Hamrin (in 1972) 4 already recognized the systemic nature of GCA, clinicians have generally viewed GCA as a predominantly 'headache disease' characterized by cranial symptoms. This perception was perhaps fostered by the 1990 ACR classification criteria for GCA, which have frequently been misused for diagnosing this disease. The ACR criteria focus on cranial symptoms such as headache and swelling and/or tenderness of the temporal artery 5, 6 . However, routine use of vascular imaging has demonstrated that large-size vessels are involved in GCA more frequently than previously thought, leading to a broader understanding of GCA as a 'vasculitic' syndrome that includes large-vessel vasculitis and PMR 6 . Large-vessel GCA (LV-GCA), a subset of GCA, affects large, supra-aortic arteries, their branches and/or the aorta and it is frequently discovered on vascular imaging studies conducted in patients with difficult-to-treat polymyalgia and/or with constitutional symptoms such as weight loss, night sweats and fever of unknown origin 1, 6 . LV-GCA-related arterial stenosis can result in upper limb claudication. Aortic inflammation is often associated with constitutional symptoms and can lead to the formation of aneurysms that cause abdominal, thoracic and/or back pain if complicated by intramural haematoma, dissection or rupture 7 . PMR is clinically characterized by aching and stiffness in the cervical region, shoulder and pelvic girdles 8 . The most feared complication of GCA is irreversible sight loss. Cerebrovascular strokes, infarction of the tongue and scalp necrosis are less common complications of this disease 9 . Permanent visual loss caused by anterior ischaemic optic neuropathy (AION) occurs in 15-20% of patients with GCA 10,11 ; improved diagnosis and prompt initiation of therapy has reduced the ischaemic complications of GCA, including those associated with sight 12, 13 . Glucocorticoids are the standard treatment for GCA and PMR even though glucocorticoid-related adverse events occur in up to 85% of treated cases 14 . Many patients have pre-existing co-morbidities that may pose relative or absolute contraindications to gluco corticoid therapy. The prevalence of flares is high, and it is related to the dose and duration of glucocorticoid therapy. In cohort studies flares were observed in 34-62% of patients [15] [16] [17] , and the results of clinical trials in which glucocorticoid treatment was rapidly tapered Abstract | The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
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. Although reports by Horton (in 1932) 2 , Paulley and Hughes (in 1960) 3 and Hamrin (in 1972) 4 already recognized the systemic nature of GCA, clinicians have generally viewed GCA as a predominantly 'headache disease' characterized by cranial symptoms. This perception was perhaps fostered by the 1990 ACR classification criteria for GCA, which have frequently been misused for diagnosing this disease. The ACR criteria focus on cranial symptoms such as headache and swelling and/or tenderness of the temporal artery 5, 6 . However, routine use of vascular imaging has demonstrated that large-size vessels are involved in GCA more frequently than previously thought, leading to a broader understanding of GCA as a 'vasculitic' syndrome that includes large-vessel vasculitis and PMR 6 . Large-vessel GCA (LV-GCA), a subset of GCA, affects large, supra-aortic arteries, their branches and/or the aorta and it is frequently discovered on vascular imaging studies conducted in patients with difficult-to-treat polymyalgia and/or with constitutional symptoms such as weight loss, night sweats and fever of unknown origin 1, 6 . LV-GCA-related arterial stenosis can result in upper limb claudication. Aortic inflammation is often associated with constitutional symptoms and can lead to the formation of aneurysms that cause abdominal, thoracic and/or back pain if complicated by intramural haematoma, dissection or rupture 7 . PMR is clinically characterized by aching and stiffness in the cervical region, shoulder and pelvic girdles 8 .
The most feared complication of GCA is irreversible sight loss. Cerebrovascular strokes, infarction of the tongue and scalp necrosis are less common complications of this disease 9 . Permanent visual loss caused by anterior ischaemic optic neuropathy (AION) occurs in 15-20% of patients with GCA 10, 11 ; improved diagnosis and prompt initiation of therapy has reduced the ischaemic complications of GCA, including those associated with sight 12, 13 . Glucocorticoids are the standard treatment for GCA and PMR even though glucocorticoid-related adverse events occur in up to 85% of treated cases 14 . Many patients have pre-existing co-morbidities that may pose relative or absolute contraindications to gluco corticoid therapy. The prevalence of flares is high, and it is related to the dose and duration of glucocorticoid therapy. In cohort studies flares were observed in 34-62% of patients suggest that sustained remission is achieved in only 15-20% of patients treated with glucocorticoids alone 18, 19 . Methotrexate, in combination with glucocorticoids, can be used to treat individuals with GCA and PMR [20] [21] [22] [23] ; however, more effective treatment strategies are needed to lower the burden from long-term use of glucocorticoids. A better understanding of the pathogenesis and clinical phenotypes of GCA will facilitate the identification of new targeted therapies that can provide safe, sustained remission and prevent disease relapse
.
In this Review, we discuss the challenges encountered in studying the epidemiology of GCA subsets, the emergence of novel imaging techniques and their role in the diagnosis, monitoring and outcome prediction of GCA and PMR. Furthermore, we present a summary of our current understanding of the pathogenesis of GCA and the possible role of novel drugs in the treatment of GCA and PMR.
GCA and PMR: frequency and epidemiology PMR is considered to be the second most common rheumatic disease in the elderly and, in countries where GCA is known to occur, GCA is the most frequent primary vasculitis 24, 25 . The epidemiology of these conditions is challenging to study because of their common clinical and subclinical overlap. Large-scale epidemiological studies of GCA and PMR are lacking in several parts of the world, including Latin America, South Asia and Africa. The highest incidence of GCA and PMR is seen among populations of Northern European ancestry (and particularly in individuals of Scandinavian descent) in which the incidence of GCA and PMR, respectively, ranges from 18 to 29 and from 41 to 113 cases per 100,000 among people aged ≥50 years [25] [26] [27] [28] [29] [30] [31] [32] . It is likely that the occurrence of GCA worldwide will increase due to ageing of the population. Indeed, the projected worldwide disease burden of GCA by 2050 is >3 million, and ~500,000 people will be visually impaired owing to GCA by 2050 (REF. 33 ).
Features of PMR are observed in 40-60% of patients with GCA at the time of diagnosis, and 16-21% of patients with PMR have GCA 1 . Subclinical GCA in patients with PMR can be detected by vascular imaging, but such imaging is not commonly performed in patients who seem to have PMR alone. Another difficulty is that there are no definite diagnostic tests for PMR and, even for GCA, the gold standard diagnostic test of temporal artery biopsy (TAB) is positive in only 39-87% of cases, and in <60% of patients with predominant LV-GCA [34] [35] [36] [37] [38] [39] . LV-GCA occurs in up to 83% of patients with GCA and with unknown frequency in PMR. GCA may coexist in patients with PMR that have an incomplete response to glucocorticoids, constitutional symptoms and markedly elevated levels of acute phase reactants 40, 41 . LV-GCA can be present when GCA is diagnosed or can occur at any point during the disease course, and it is detected with increasing frequency in patients with GCA after 4-5 years of disease 42 . The definition of LV-GCA is still imprecise, which hinders epidemiological studies. As biopsy of larger arteries is not feasible in routine practice, LV-GCA is diagnosed by use of imaging methods such as axillary ultrasonography, 18 F-FDG-PET, CT angiography (CTA) or MRI. All of these techniques assess mural inflammation and ultrasonography, CTA and MRI additionally investigate changes in the lumen.
Our revised understanding of GCA as a complex disease that is not limited to cranial arteries, along with advanced imaging techniques and international efforts to better define the disease, will facilitate future studies on the epidemiology of GCA and our understanding of its incidence, prevalence and disease course.
The role of imaging in GCA and PMR Although imaging in GCA and PMR is evolving quickly, controversy persists concerning which imaging techniques to use when, and whether imaging is a reliable outcome parameter and/or tool for monitoring GCA and PMR.
Imaging techniques for diagnosing GCA and PMR. The majority of imaging studies have been performed to assess the potential of ultrasonography in diagnosing GCA and PMR. In GCA, ultrasonography has not yet replaced TAB, although several studies report a sensitivity of 55-100% and a specificity of 78-100% in the ability of ultrasonography to detect a 'halo' sign, which is a non-compressible
Key points
• Giant cell arteritis (GCA) is best understood as an inflammatory vascular syndrome with features of cranial and/or large-vessel vasculitis, systemic inflammation and polymyalgia rheumatica (PMR), which frequently overlap • GCA and PMR are among the most common inflammatory rheumatic diseases in the elderly; the prevalence of these diseases is expected to increase due to ageing of the population • The role and value of imaging in GCA and PMR is evolving quickly • The pathophysiology of GCA is characterized by phases of initiation, transmural inflammation and chronic vessel wall injury and repair, each of which might be novel drug targets • Glucocorticoids are the standard-of-care treatment for GCA and PMR, although methotrexate is used in individual cases and anti-IL-6 therapy is now approved for the treatment of GCA • The selection of patients for biologic DMARD therapy, defining the best treatment strategies and the development of reliable outcome parameters are challenges in the future management of GCA and PMR hypo-echoic ring around the artery lumen reflecting inflammation of the vessel wall 1, 35, [43] [44] [45] . The TABUL study prospectively compared the performance of colour Doppler ultrasonography and TAB for the diagnosis of GCA, reporting sensitivities of 54% and 39% and specificities of 81% and 100%, respectively. As TAB was part of the reference standard, the higher specificity of TAB could be an artefact of the study methodology 36 . Although PMR is diagnosed clinically, ultrasonography can improve the accuracy of diagnosis and it has therefore been included in the ACR-EULAR classification criteria for PMR 46, 47 . A characteristic lesion in PMR that can be detected by use of ultrasonography is suba cromial bursitis or subdeltoid bursitis; the sonographic detection of these lesions diagnoses PMR with a sensitivity of 79% and a specificity of only 59% 48 . This low specificity relates to a true overlap between PMR and inflammatory arthritis as ultrasonography was better at distinguishing PMR from non-inflammatory mimics 46, 47 . 18 F-FDG-PET can establish a diagnosis of GCA in patients presenting with marked systemic symptoms and/or elevated levels of inflammatory markers without characteristic features of cranial GCA, and it can also be used to search for alternative diagnoses in patients with unexplained illness and a low probability of GCA 49 . 18 F-FDG-PET visualizes local glucose metabolism; as vascular inflammation is associated with increased glucose consumption, enhanced tracer uptake in the vessel wall suggests vasculitis. In patients with PMR, 18 F-FDG-PET has revealed increased glucose metabolism in the shoulder and hip girdle as well as the presence of lumbar interspinous bursitis and cervical interspinous bursitis 50, 51 . One study also reported bilateral uptake of tracer in the fibrous capsule at the knees in 84% of patients with PMR 52 .
18
F-FDG-PET has also revealed that LV-GCA is present in up to 30% of individuals with PMR and is more likely to be present in patients who have PMR with anaemia, markedly elevated inflammatory markers and disease that is relapsing or resistant to treatment than in patients who have (treatable) PMR alone 51, [53] [54] [55] . CTA and magnetic resonance angiography (MRA) enable the detection, in GCA, of soft tissue swelling or cuffing of the wall of large arteries and of the aorta, and also provide information about the luminal ana tomy and blood flow. These techniques are thus helpful for detecting GCA-related vascular stenosis or aneurysms 56, 57 , although the sensitivity and specificity of these techniques for establishing a diagnosis of GCA is still unclear.
The role of high-resolution (3 Tesla (3T) and 7T) MRI in the investigation of cranial arteries in GCA is evolving. A multicentre trial comparing the ability of MRI (1.5T used in 55 patients and 3T in 130 patients) and TAB to detect cranial vasculitis in patients suspected to have GCA demonstrated a sensitivity for MRI (pooled analysis for 1.5T and 3T) of 88% and a specificity of 75% 58 . Exciting preliminary data suggests that new generation 7T MRI is even more sensitive than 3T MRI for detailing the segments of the temporal artery that are inflamed in GCA 59 . High-resolution MRI might also detect inflammation in both the deep temporal arteries and temporalis muscle, which is useful in patients where GCA is strongly suspected but the superficial temporal arteries appear normal 60 . The limited availability of 3T MRI and 7T MRI, however, restricts the clinical utility of this imaging modality in diagnosing and monitoring GCA.
Another pilot study of 12 patients with GCA or Takayasu arteritis observed that use of 18 F-FDG-PET with MRI had better soft tissue resolution and was optimal for determining disease extent for both diseases as compared with 18 F-FDG-PET with CT 61 . The performance of these imaging techniques was comparable when assessing the aorta and large vessels in GCA and Takayasu arteritis.
The value of imaging in monitoring GCA and PMR. The value of ultrasonography for assessing inflammation at temporal arteries is limited because the halo sign that is characteristic of GCA disappears after 2-4 weeks of glucocorticoid treatment and re-appears only in cases of major relapse 44, [62] [63] [64] . Whether the extent, persistence or re-appearance of the halo sign at the temporal arteries is of any prognostic value for patients with GCA requires further investigation. Ultrasonography of large arteries such as the carotids or the axillary artery might be more useful for monitoring disease because wall swelling in these larger arteries persists longer than in superficial cranial arteries despite therapy 43 . Changes in the artery intima and media thickness during follow-up ultrasonography might reflect alterations of disease activity, but prospective evaluation is still needed to establish the importance of these changes 65 .
Box 1 | Unmet needs in giant cell arteritis and polymyalgia rheumatic
There are still many unmet needs in the clinical assessment and treatment of giant cell arteritis (GCA) and polymyalgia rheumatic (PMR). The top three unmet needs of different aspects of GCA and PMR are listed here.
Epidemiology
• Epidemiology and the extent of overlap between the GCA phenotypes of cranial GCA, large-vessel GCA (LV-GCA) and PMR • Prevalence of subclinical GCA in clinically isolated PMR • Expected increment of GCA and PMR incidence due to ageing of the population 
Imaging

Treatment
• Optimize the use of glucocorticoids and glucocorticoid-sparing agents • Study novel treatment targets in GCA and PMR • Define outcome parameters and identify prognostic factors for the stratification of treatment 18 F-FDG-PET, which is typically performed with CT, exposes patients to a radiation dose of 10-15 μSv, which precludes its routine use in follow-up investigations. Moreover, there is also uncertainty concerning the relationship between low-grade FDG uptake and arterial wall inflammation. In one prospective study, the level of arterial FDG uptake decreased following 3 months of glucocorticoid treatment. as compared with the level of uptake observed at the time of GCA diagnosis; however, no further reduction in uptake was seen at 6 months post-treatment despite clinical remission of GCA 40 . FDG uptake at 6 months post-treatment could reflect persistent arterial wall inflammation but it might also represent myofibroblast proliferation, fibrosis or the presence of atheroma, all of which consume glucose.
Longitudinal follow-up studies using MRA and CTA in GCA are scarce. In a prospective study, CTA scans were scheduled in 35 biopsy-proven cases at diagnosis and after 1 year of glucocorticoid treatment. Although arterial wall thickening was still present in 68% of cases after 1 year of treatment, the number of affected arterial segments, arterial wall thickness and contrast enhancement in the artery had decreased with therapy. No patients developed worsening of, or new, aortic dilation after 1 year of treatment, suggesting that aneurysm formation is a delayed complication in most patients with GCA 66 . This observation is in accordance with previous retrospective studies 42, 67, 68 . Lack of radiation exposure with MRI, as well as the option to use gadolinium-based contrast agents to distinguish active arterial wall inflammation from fibrosis, makes MRA an attractive tool for the follow-up of GCA, particularly in patients with LV-GCA 69 . The lower spatial resolution and longer scan times of magnetic resonance compared with CTA, and the infrequent but serious nephrotoxicity of gadolinium, are disadvantages of MRA.
No consensus exists regarding the screening for stenosis and aneurysms of large arteries and the aorta. Researchers attempt to obtain a baseline image of large arteries and the aorta in all patients with GCA (this information is especially useful in the assessment of patients with symptoms of LV-GCA), although there are no data proving the cost-effectiveness of this approach. Patients with an aortic diameter outside the sex and agematched normal range and those with active aortitis or risk factors for the development of aortic aneurysms (for example, smokers, patients with hypertension and patients with pre-existing cardiovascular disease) might then be followed-up every 1-2 years with MRA to detect possible aortic dilatation while minimizing radiation exposure 70, 71 . In patients that do not meet these criteria, axillary artery ultrasonography, chest radiography, echocardiogram and abdominal sonography every other year might be sufficient for monitoring disease progression, with any observed change in aortic diameter prompting further investigation 22 .
Emerging developments in the imaging of GCA and PMR. The ability to reliably detect low-grade 'grumbling' arterial wall inflammation and early disease relapse in patients with GCA who are receiving treatment is desirable. New approaches to achieve this goal include the search for novel, specific PET ligands. PK11195 binds specifically to translocator protein, which is highly expressed on activated neutrophils, monocytes and macrophages.
[ 11C ]-PK11195 identified the five patients with active disease among 15 patients with GCA and Takayasu arteritis with high sensitivity 72 . A small study of patients with GCA and Takayasu arteritis comparing colour Doppler ultrasonography with microbubble contrast-enhanced ultrasonography reported that the latter is optimal for the assessment of arterial wall lesions and that it detects neovascularization 73 . Moreover, initial evidence suggests that contrast-enhansed ultrasonography can quantify disease activity in patients with GCA and Takayasu arteritis and monitor the response to treatment in carotid arteritis [74] [75] [76] . Ischaemia of the optic nerve head, retina and choroid must also be assessed in patients with GCA. Traditionally fluorescein and indocyanine green angiography have been used in such assessments but these techniques are invasive and patients are at risk of allergic reactions to the dyes. Optical coherence tomography (OCT) is a noninvasive interferometric optical mode of imaging that could be of particular use in differentiating non-arteritic AION from GCA-related AION 77 .
OCT uses motion-contrast imaging to produce highresolution volumetric blood flow information that enables visualization of the distinct retinal, chororetinal and choroidal capillary networks 78, 79 . In GCA, this technique might be applied to identify patients at risk of visual loss.
Understanding the pathogenesis of GCA The current concept of GCA is that of an immunemediated disease of large vessels; cranial arteries and/or the aorta and its major branches are thought to be the most frequent targets of this disease. Inflammation starts in the adventitia and spreads to the inner layers of the vessel wall. Patients with isolated PMR or poly myalgic syndrome in association with elderly onset inflammatory rheumatic diseases, such as rheumatoid arthritis (RA), are affected by a systemic inflammatory syndrome in conjunction with bursitis and synovitis of shoulders, hips and the spine 6 . PMR in association with GCA is regarded by some as an early or aborted form of vasculitis where vascular inflammation is often limited to the adventitia and periadventitial small vessels 80 . The acute phase of GCA is mainly inflammatory, whereas the chronic stages are characterized by inflammation, degradation and repair mechanisms that collectively lead to structural changes of the vessel wall, ischaemic complications and aneurysm development (FIG. 1) . TABLE 1 highlights areas of future research based on the current understanding of the pathogenesis of GCA and PMR and notes potential biomarkers and treatment targets.
The role of inflammation in the initiation of GCA. The trigger for the inflammatory cascade resulting in GCA is still unclear. The adventitia is an important site of immune surveillance and it is rich in dendritic cells (DCs) expressing Toll-like receptors (TLRs) and in macrophages 81 . In GCA, these cells become aberrantly activated via • Anti-IL-6R
• Co-stimulation blocker
Anti-TNF VSMCs Ectopic lymphoid structures and chemokines, factors important in the chronic phase of GCA include VEGF, platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) produced by macrophages and endothelin-1 produced by endothelial cells and vascular smooth muscle cells (VSMCs), which activate inflammatory cells, VSMCs, stromal cells, pericytes and endothelial cells to induce the formation of new vessels and promote VSMC migration, fragmentation of the external and internal elastic lamina by metalloproteinases and endothelial cell proliferation. Ectopic lymphoid structures are formed within the adventitia in this phase of chronic inflammation and remodelling. Possible treatment approaches include prevention of DC activation in the initiation phase of GCA by use of antimicrobials, blockade of cytokines, chemokines, co-stimulatory pathways, Notch and signalling pathways by use of biologic and/or synthetic drugs in both the initiation and amplification phases of GCA, and blocking growth factors (including VEGF, PDGF and FGF), neurotrophins and cytokines in the chronic phase of GCA. Green boxes show treatments for GCA proven effective in RCTs; grey boxes show other potential treatment options for GCA; the red box shows a treatment that failed to show efficacy in clinical trials.
pathogen-associated molecular patterns (PAMPs) or microorganism-associated molecular patterns (MAMPs), leading to the production of pro-inflammatory cytokines such as IL-1 and IL-6 and the activation of T cells. A low level of expression of the co-inhibitory molecule programmed cell death 1 ligand 1 (PD-L1) by DCs in GCA seems to accelerate the recruitment and retention of T cells in the inflamed artery 82 . CD8 + CCR7
+ regulatory T cells with reduced expression of cytochrome b-245 heavy chain (also known as NADPH oxidase 2 (NOX2)) were detected in the peripheral blood of patients with GCA, resulting in decreased suppression of CD4 + T cell responses 83 . In healthy individuals, CD8 + CCR7 + cells release NOX2-containing vesicles that are taken up by interacting CD4 + T cells, thereby inhibiting their activation, and T cells, macrophages and other immune cells eventually cause tissue damage in the media and adventitia and the release of damage-associated molecular patterns (DAMPs). DAMPs are increased in aged vessels where they act synergistically with PAMPs to further stimulate the inflammatory process 84 . Using advanced DNA sequencing techniques, one study observed abundant viral and bacterial DNA in the arterial wall of patients with GCA 85 . Earlier studies recurrently observed various bacterial strains (such as chlamydia and Burkholderia) or viruses (such as parvovirus B19 and varicella zoster virus) in temporal arteries, collectively supporting the hypothesis that PAMPs and MAMPs are crucial for the onset of GCA. No specific GCA-causing microorganism that might be targeted by anti-infective agents has been identified [86] [87] [88] . Treatment strategies directed at silencing DCs and adventitial macrophages at an early stage include the inhibition of IL-1 and IL-1β by drugs such as 90 . In addition to CD4 + T cells, a small proportion of CD8 + T cells also infiltrates into the temporal artery in response to signals from CXCR3, producing IL-17 and IFNγ as well as perforin 1 and granzyme B. The level of perforin 1 and granzyme B produced seems to correlate with the extent of vessel wall destruction and disease severity 89 . IL-17 and IL-6 also regulate the crosstalk between T cells and a newly discovered subset of neutrophil granulocytes. In one study, AnxA1 ; these neutrophils were unable to control T cell responses 91 . Cytokine and chemokine gradients also orchestrate the migration of tissue-destructive monocytes, macrophages and B cells to amplify inflammation following the onset of GCA and, in parallel, neoangiogenesis is stimulated by VEGF that is released mainly by macrophages 92, 93 . Targeting IL-6 receptor with tocilizumab and IL-6 with sirukumab, and blocking IL-17 with secukinumab or IL-12 and IL-23 with ustekinumab, as well as modulating chemokines or intracellular signalling pathways such as the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway with inhibitors, might interrupt the feed-forward loops and terminate the amplification of inflammation.
IL-6 has a pivotal role in the pathogenesis of the systemic inflammatory response, whereas the recruitment of media-infiltrating macrophages, giant cell formation and the proliferation of VSMCs in GCA might also be driven by pro-inflammatory factors such as TNF and IFNγ 89, [93] [94] [95] [96] . JAK family members form homodimers or heterodimers to mediate the signalling of different cytokines 97 . IFNγ signals though JAK1-JAK2 heterodimers whereas type II cytokine receptors such as those for IL-6 and IL-1 mainly signal through JAK1 homodimers 98, 99 . The JAK inhibitor tofacitinib preferentially blocks signalling by cytokine receptors that are associated with JAK3 and/or JAK1 (REFS 100,101). Baracitinib has selectivity for JAK1 and JAK2 dependent cytokine receptors and thereby targets T H 1 and T H 17 cells 102 . JAK1 and JAK2 dependent cytokine receptors are not exclusively expressed on T H 1 and T H 17 cells but, after binding of IFNγ and IL-6, they phosphorylate STAT1 and STAT3, which activate T-bet (T H 1 transcription factor) and RORγt (T H 17 transcription factor). Apremilast, which is effective in psoriatic arthritis and Behçet syndrome 103, 104 , binds to the catalytic site of the phosphodiesterase 4 (PDE4) enzyme and blocks the degradation of cyclic AMP (cAMP) 105 ; the increased levels of cAMP result in a reduction in T H 1, T H 2, and T H 17-mediated immune responses and in the production of IFNγ, TNF, IL-12, IL-17 and IL-23, all of which have an important role in the pathogenesis of GCA 106, 107 . Whereas these are promising agents to halt the transmural and/or systemic inflammation in GCA or PMR, there are no reports of JAK inhibitors or apremilast for treating these diseases.
Although B cells are present in temporal artery tissue of patients with GCA, their role in the pathogenesis of GCA and PMR has only recently been explored 108 . Circulating B cell levels are decreased in patients newly diagnosed with GCA or PMR and these levels recover rapidly once remission is achieved 92 . One study described the occurrence of tertiary lymphoid organs in the medial vessel-wall layer of temporal arteries, in close proximity to high endothelial venules, in 60% of patients with GCA 109 . It is also known that B cells can function as antigen-presenting cells and that they could thus provide the co-stimulatory signals required for the clonal expansion of CD4 + T cells 110 .
Arterial remodelling and vascular occlusion in GCA.
In GCA, several mediators contribute to intimal hyperplasia and vascular occlusion. Platelet-derived growth factor (PDGF), for example, caused arterial occlusion in cultured primary myointimal cells derived from the human temporal artery and also stimulated the production of angiogenic factors (such as angiogenin) and chemoattractants (such as CCL2) 111 . In temporal artery specimens from patients with GCA, macrophages producing PDGFA and PDGFB were located at the mediaintima junction, particularly in cases with concentric intimal hyperplasia 94 . Neurotrophins are growth factors that mediate the differentiation and survival of neurons and vascular cells. In GCA, nerve growth factor (NGF; predominately expressed in adventitia and media), brain-derived neurotrophic factor (BDNF; media and intima) and the neurotrophin co-receptor sortilin (adventitia and intima) were overexpressed in different histological layers of temporal arteries. In vitro, NGF and BDNF promoted the proliferation of VSMCs and BDNF also facilitated the migration of temporal artery VSMCs. Sortilin amplified proliferation and migration of VSMCs, functioning as an intracellular protein transporter for immature neurotrophins and as a regulator of BDNF trafficking and release 112 . Endothelin-1 and endothelin B receptor are also expressed in GCA lesions, particularly on VSMCs and multinucleated giant cells 113 . Endothelins might contribute to the pathogenesis of GCA by promoting inflammation, increasing the sensitivity of the lesion to vasoconstriction, increasing VSMC proliferation and stimulating the migration of VSMCs towards the intimal layer; these events collectively contribute to intimal hyperplasia and vascular occlusion [114] [115] [116] . Macrophages and giant cells from patients with GCA release VEGF; VEGF eventually leads to endothelial cell growth, neo-angiogenesis and vasa vasorum formation 93 . Whether local hypoxia (resulting from the high oxygen consumption of inflammatory and stromal cells) or pro-inflammatory cytokines drive VEGF secretion needs to be elucidated 117 . Macrophages also produce proteases (including matrix metalloproteinases (MMPs), cathepsins and neutrophil elastase), which have an important role in the emergence, and branching, of vasa vasorum 118 . Whether vascular remodelling and intimal hyperplasia can be influenced by immunosuppressive therapies is unclear. One study obtained paired TABs from four patients (one treated with glucocorticoids, three with gluco corticoids and infliximab) at baseline and after 1 year of therapy, and reported that mRNA levels of inflammatory cytokines were decreased in arterial tissues whereas the mRNA levels corresponding to proteins that mediate vascular remodelling (such as MMP9, TGFβ, PDGFA and PDGFB) were increased 107 . Another study observed that tissue concentration of endothelin was similar in temporal artery specimens from patients with active disease and from patients with inactive (that is, treated) disease 116 .
Further research is necessary to better understand the factors contributing to arterial remodelling and vascular occlusion in GCA and to determine how these processes can be interrupted. Although direct inhibitors of proliferative or pro-angiogenic factors hold promise, they could disrupt terminal arterial vascularization, such as of the vessels supplying the optic nerve, worsening ischaemic complications.
Improving the benefit of glucocorticoids
Glucocorticoids remain the mainstay treatment of both PMR and GCA, but the basis for the use of different glucocorticoid dosages in different clinical conditions is empiric 1 . According to consensus-based recommendations, the initial therapy is prednisone equivalent 12.5-25 mg per day for PMR and 40-60 mg per day for GCA, followed by individualized tapering regimens [20] [21] [22] 119 . Optimizing the benefit:risk ratio of glucocorticoids to minimize adverse events while achieving sustained remission is an ongoing challenge 120 . Improved implementation of current treatment recommendations for the optimal use of glucocorticoids could reduce the burden of this treatment [20] [21] [22] . A EULAR task force concluded that the risk of glucocorticoid-related harm for the majority of patients taking glucocorticoids for a prolonged period (that is, for 3-6 months or more) is low if doses of ≤5 mg per day prednisone equivalent are prescribed, but high if doses >10 mg per day are used. At doses between 5 mg and 10 mg per day, patient-specific risk factors determine the probability of harm.
The development of innovative glucocorticoid preparations and/or glucocorticoid receptor ligands might also increase the benefit:risk ratio of glucocorticoids. A novel class of glucocorticoids are the dissociated agonists of the glucocorticoid receptors (DAGR; also known as selective glucocorticoid receptor modulators (SEGRMs)) 121 . DAGRs predominately trans-repress products of glucocorticoid target genes that mediate anti-inflammatory effects without markedly transactivating the products of glucocorticoid target genes that are responsible for the adverse effects of these drugs 122 .
Liposomal glucocorticoids have been designed to deliver conventional glucocorticoids to inflamed tissues using very small, nanometre-sized liposomes 123 . This technology could provide strong therapeutic effects and cause minimal systemic adverse events. DAGRs and liposomal glucocorticoids are currently being evaluated in RA; trials in PMR and GCA could follow if the results of these RA trials are favourable.
Finally, modified-release prednisone was shown to enable optimal chronotherapy with bedtime administration and the release of prednisone at the optimal time for suppression of pro-inflammatory cytokines (that is, at approximately 2 a.m.). Although modified-release prednisone was clinically superior to conventional prednisone in the treatment of RA (according to the CAPRA-1 and CAPRA-2 randomized controlled trials) 124, 125 , the multicentre randomized, phase III study in PMR was terminated early because of insufficient recruitment (only 62 of a planned 400 patients were included), which meant that this study failed to meet its primary endpoint 126 . Modified-release prednisone has also been studied in a small phase II trial including 12 patients with new-onset GCA. At 26 weeks, there was no difference between patients treated with modified-release prednisone as compared with patients treated with immediate-release prednisolone in terms of reduction in inflammatory markers, pain, fatigue and quality of life 127 .
Emerging therapies for GCA and PMR
There is a need for glucocorticoid-sparing agents in the treatment of GCA and PMR. Methotrexate is currently the only conventional DMARD, if administered along with glucocorticoids, that demonstrates even a modest reduction of the cumulative glucocorticoid dose in systematic reviews and meta-analyses in GCA and PMR 23, 128 , although individual trials have reported that adjuvant methotrexate had no effect on the dose of glucocorticoid required to successfully treat GCA and PMR [129] [130] [131] . Current EULAR recommendations are conditionally in favour of using methotrexate in a subpopulation of patients with GCA and PMR 21, 119 . For the use of other conventional DMARDs, such as azathioprine, mycophenolate mofetil, cyclophosphamide, ciclosporin or dapsone, in treating GCA and PMR there are either insufficient data from trials or the DMARD was ineffective or toxic in small, usually low quality, clinical studies 1 . Case series have shown some potential benefit of the DMARD leflunomide in patients with refractory GCA and PMR 132, 133 ; however, prospective evaluation of this drug in randomized controlled trials is still needed.
TNF antagonists were the first biologic agents studied in both GCA and PMR, either as monotherapy (in PMR) or in combination with glucocorticoids (in PMR and GCA). Initial case reports and case series revealed promising results; however, the results of randomized controlled trials of infliximab and etanercept (for the treatment of GCA and PMR) and of adalimumab (for the treatment of GCA) were disappointing [134] [135] [136] [137] [138] (TABLE 2). There is no clear explanation for the failure of these drugs, but there may be redundant pathways that render TNF blockade insufficient in treating these diseases. The results from recent trials of tocilizumab in GCA have generated optimism for this approach. A phase II 52-week study of 30 patients with GCA suggested that treatment with intravenous tocilizumab in combination with a short cycle of glucocorticoids resulted in higher remission rates, lower cumulative glucocorticoid doses, and a shorter duration of glucocorticoid therapy compared with placebo treatment 18 . In the phase III GiACTA trial, 119 newly diagnosed patients and 132 patients with relapsing GCA were randomly assigned to receive weekly or every-otherweek subcutaneous tocilizumab in combination with a 26-week prednisone taper, or to one of two placebo arms in which prednisone was tapered over 26 or 52 weeks 19 . The primary outcome of sustained prednisone-free remission (defined as the absence of a disease flare and normal C-reactive protein (CRP) levels) at week 52, was achieved in 56% of the patient group that received tocilizumab weekly and in 53% of the patient group that received tocilizumab every other week. By contrast, only 14% of patients in the placebo arm in which prednisone was tapered over 26 weeks, and 18% of patients in the placebo arm in which prednisone was tapered over 52 weeks, achieved the end point. Because of the direct influence of tocilizumab on acute phase reactants, a sensitivity analysis was conducted excluding CRP levels from the definition of sustained remission. This analysis confirmed the primary results. Other outcomes, such as the proportion of patients with at least one flare or quality of life, were also better in the tocilizumab-treatment groups. The cumulative glucocorticoid dose was ≥40% lower in tocilizumab-treated patients than in glucocorticoidtreated patients and serious adverse events occurred in 14-15% of tocilizumab-treated patients compared with 22-26% of patients in the placebo groups. Whether the rate of serious adverse events and cumulative glucocorticoid dose were directly related is unclear, as the study was not powered to investigate such an association. Longer follow-up of patients treated with tocilizumab is now required to determine the durability of remission and the safety of tocilizumab. On the basis of the results of GiACTA and other trials, tocilizumab has been approved by the FDA for use in GCA 19 . In PMR, two prospective open-label studies of tocilizumab (one with accompanying glucocorticoids and one without; neither study included a proper control group) reported achieving the primary efficacy end point, namely low disease activity at 12 weeks, defined as PMR activity score (PMR-AS) ≤10, or glucocorticoid-free remission at 6 months, in 100% of patients 139, 140 . The PMR-AS combines, into a quantitative score, the patient's assessment of pain and the physician's global assessment, both of which are assessed on a 0-10 visual analogue scale, with the duration of morning stiffness, the elevation of the upper limbs (a semi-quantitative assessment scored on a 0-3 scale) and CRP levels. CTLA-4, cytotoxic T-lymphocyte protein 4; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; PMR-AS, polymyalgia rheumatica activity score.
These studies complement the evidence from numerous case reports, case series and small non-randomized studies reporting a benefit of tocilizumab in PMR and GCA [141] [142] [143] [144] . The data on PMR, however, are still insufficient to recommend tocilizumab treatment for this condition other than in trials or in exceptional cases, such as in glucocorticoid-resistant disease or when glucocorticoids are contraindicated.
A phase III study of the IL-6 blocker sirukumab or placebo plus glucocorticoids in GCA is ongoing. Recruitment is expected to be completed in the second half of 2017 and the first results could be available by the end of 2018 (REF. 145 ).
Continuing with other cytokine inhibitors, a proof-of-concept study assessed the efficacy in PMR of canakinumab, an IL-1β inhibitor, and secukinumab, an IL-17 inhibitor, in comparison with glucocorticoid therapy 146 . This trial failed to meet its primary end point but the observational period of 2 weeks might have been too short to demonstrate any notable effects. A study of the anti-IL-1β antibody gevokizumab in GCA was terminated early because of the negative outcome of a trial of this agent in Behçet disease 147, 148 . Ustekinumab, which blocks IL-12 and IL-23, has been studied in a small open-label trial of patients with treatment-refractory GCA in which ustekinumab was given along with glucocorticoids 149 . A reduction in features of disease activity leading to reduction of the glucocorticoid dose as well as the possibility for discontinuing other immunosuppressive agents was reported 149 . The role of this agent for treatment of GCA outside of clinical trials remains to be defined.
Inhibiting T cell activation and halting the inflammatory cascades that lead to transmural inflammation by T cells and macrophages might halt the destruction of the arterial wall in GCA 150, 151 . Blocking T cell co-stimulatory signals with abatacept was compared with placebo, in a small RCT in GCA which included glucocorticoids in both treatment arms 152 . A markedly higher rate of relapse-free remission was achieved after 12 months in the abatacept group compared with the placebo group. The majority of T cells in the arterial wall of patients with GCA, however, are effector cells lacking co-expression of CD28, the interaction of which with B7 molecules is usually targeted by abatacept 84 . This observation raises the intriguing possibility that the success of this study could relate to an off-target effect of abatacept in GCA. Interestingly, in Takayasu arteritis, abatacept was no more effective than placebo in maintaining remission 153 . A few cases of GCA have also been treated successfully with rituximab (a B-cell depleting monoclonal antibody therapy), suggesting that placebo-controlled trials might be warranted to better study this agent for its ability to maintain remission and to enable glucocorticoid-sparing in GCA 154, 155 . The role for biologic DMARDs in treating GCA and PMR is emerging and these drugs could become routine clinical care in the near future. The successful use of biologics with subsequent rapid tapering of glucocorticoids could markedly reduce the burden of glucocorticoidrelated adverse effects.
Future treatments for GCA and PMR To ensure the optimal treatment of GCA and PMR in the future, it is important to determine which patients will benefit from treatment with biologic agents, how biologic agents can be used and what the best treatment targets for GCA and PMR are.
Which patients with GCA and PMR will benefit from biological agents? The current unmet clinical need in GCA and PMR is the treatment of patients with a persisting high burden of inflammatory disease, multiple relapses with an inability to wean glucocorticoids, non-response to methotrexate, co-morbidities and other factors that increase glucocorticoid-related adverse events, and resistance to glucocorticoid therapy 17, 70, [156] [157] [158] [159] . It is anticipated that biologic agents, particularly IL-6 inhibitors, will first be used in these subpopulations even though clinical trials have focused on patients with new-onset or relapsing disease 18, 139, 140 . Biologic agents might also be used early in patients at risk of disease complications and/or treatment-related adverse events. Unfortunately, the majority of data on prognostic factors in PMR and GCA are weak or contradictory, impeding the definition and identification of the 'at risk' population 128 (C.D., B.D. and S. GonzalezChiappe, unpublished work). A pronounced inflammatory response at disease outset has been associated with a higher probability of relapse in both GCA and PMR 15, 16, 160 . Assuming that IL-6 blockade would be particularly effective in cases with high levels of systemic inflammation, these patients could benefit most from treatment with IL-6 blockers.
How will biologic agents be used in GCA and PMR therapy? A rapid response to glucocorticoids has been considered an important feature in the treatment of GCA and PMR for decades. Immediate treatment and a rapid response is also pivotal to prevent blindness in GCA 12, 13 . Although tocilizumab yielded impressive results in trials assessing its ability to maintain GCA remission, it is unclear if tocilizumab therapy without glucocorticoids will prevent vascular complications such as sight loss or aneurysms 18, 19 . The outcome parameters used in these studies mostly reflected the inflammatory response rather than underlying vessel wall damage. In PMR, tocilizumab without glucocorticoids did not rapidly improve symptoms; although 100% of patients with PMR treated with tocilizumab achieved the primary end point, improvement was more gradual than that seen with glucocorticoids 140 . A low disease activity, as defined by the PMR-AS, was achieved by less than 50% of patients after 4 weeks.
The response of patients with GCA to abatacept might also be more gradual compared with the response induced by glucocorticoids; however, due its mode of action, the effect of abatacept might be more lasting and have a greater impact on reducing vascular damage than glucocorticoids 150 . Based on these results it is unlikely that biologics will be used as monotherapy to induce remission in GCA and PMR in the near future. Instead, a short course of glucocorticoids might be required to produce a rapid improvement of symptoms, before remission is maintained by use of biologic therapies. It is unclear how long treatment with biologic agents needs to be continued once stable remission has been achieved; it might be possible to change to another agent, such as methotrexate, to maintain remission. Long-term treatment with biologics or other immunosuppressive agents might prevent late vascular complications in patients with LV-GCA, although this benefit still needs to be demonstrated in clinical studies.
What are the treatment targets in GCA and PMR? The targets for the treatment of GCA and PMR need to be more clearly defined. Whereas the remission of symptoms or the prevention of blindness are obvious treatment goals, other treatment goals -as elicited in in-depth discussions with patients as well as in patient surveys -are less clear 161, 162 . For example, patients with PMR complain about disability and fatigue, symptoms that they rated as important as pain. 'Coming off steroids' as well as 'living with steroids' were also important to individuals according to a survey conducted by the GCA and PMR charity group GCAPMRuk (REF. 163 ). In addition, remission and relapse have been defined differently in the majority of published studies 164 . Studies in GCA have used qualitative criteria of remission and relapse as outcome measures, taking into account the history and clinical assessment of GCA and/or PMR features, the physician's global assessment, erythrocyte sedimentation rate (ESR), CRP levels, blood count and fibrinogen levels. Remission was classed as the absence of abnormal findings of these parameters whereas a relapse was considered if characteristic signs and symptoms of the disease reappeared 19, 129, 134 . The absence of a relapse does not automatically imply remission. The prognostic relevance of low-grade disease activity states, which are compatible with neither remission nor relapse, is currently unclear. Trials in PMR have used either the composite PMR-AS to define remission and low disease activity or have applied qualitative remission and relapse criteria 135, 138, 140, 164, 165 . Another challenge of outcome criteria for GCA and PMR is the fact that certain agents, such as IL-6 antagonists, directly influence acute phase reactants which are integral to current remission and relapse criteria 19, 129, 134, 164, 166 . The inclusion of ESR and CRP level in outcome measures of anti-IL-6 trials might therefore produce a type I error (that is, the incorrect rejection of a true null hypothesis); however, remission and relapse criteria without a laboratory criterion are unavailable. Whether imaging of vessels involved in GCA or joints and periarticular structures in PMR, or the use of biomarkers that are independent of the acute phase response, would be a possible alternative to ESR and CRP in the remission and relapse criteria is unclear.
Another unanswered question is whether treatment decisions could be based on abnormal imaging with or without laboratory results. It might be tempting to modify treatment in a patient with GCA who has elevated acute phase reactants and positive 18 F-FDG-PET despite the absence of symptoms 40 . We do not know, however, whether these tests are reliable markers of ongoing inflammation or even predictive of future large vessel damage and resultant complications, and whether patients would benefit if treatment was changed on the basis of these parameters.
Conclusions
The understanding that GCA and PMR have over lapping clinical phenotypes, new developments in the field of imaging as well as new treatment options have raised new questions and identified unmet needs in the diagnosis, treatment and prognostics of these diseases. First, what is the true epidemiology of these diseases given the frequent clinical and subclinical overlap of cranial and large vessel disease, and the overlap of GCA and PMR? Second, do different pathophysiological pathways determine the clinical phenotype, prognosis and treatment response of GCA and PMR? Third, which biomarkers can help physicians to recognize and predict unfavourable disease outcomes of GCA and PMR? Fourth, what is the role of currently available and evolving imaging techniques for diagnosing and monitoring GCA and PMR? Fifth, how can emerging therapies be used to treat GCA and PMR and, finally, what treatment targets should be used in future clinical studies of GCA and PMR? Multinational collaboration is needed in order to conduct studies that answer these questions.
